Once scored as a potential blockbuster, Novartis’ serelaxin fizzles in critical cardio outcomes test
You can scratch serelaxin off Novartis’ list of potential blockbusters in the late-stage pipeline.
This morning the pharma giant said that its 4-year study of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
